close
Add to watchlist
Affymax Inc (AFFY)
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company's lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide. The company was founded in 2001 and is based in Palo Alto, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 11.11 |
| Volume | 817940 |
| Volume Avg | (mio) 1.18 |
| 52 Week High | 11.50 |
| 52 Week Low | 3.93 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -1.41 |
| EPS change Q/Q | -20% |
| EPS change Q/Q Yr ago | -9.09% |
| EPS change Q/Q next Q est | -43.75% |
| EPS change Y/Y | -433.9% |
| REV change Q/Q | 149.25% |
| REV change Q/Q Yr ago | -51.87% |
| EPS next Q est | -0.64 |
| EPS next Y est | -0.64 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |